Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Obesity is a prevalent global health issue affecting approximately half of the world's population.Extensive scientific research highlights the urgent need for effective obesity management to mitigate health risks and prevent complications.While bariatric surgery has proven to be highly effective, providing substantial short-term and long-term weight loss and resolution of obesity-related comorbidities, it is important to recognize its limitations and associated risks.Given the global obesity epidemic and the limitations of surgical interventions, there is high demand for effective and safe anti-obesity medications (AOMs).In Korea, the Korean Society for the Study of Obesity strongly advocates for the use of pharmacotherapy in Korean adults with a body mass index of 25 kg/m² or higher who have not achieved weight reduction through non-pharmacological treatments.Currently, five AOMs have been approved for long-term weight management: orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, and semaglutide.Tirzepatide is awaiting approval, and compounds such as CagriSema (Novo Nordisk) and oral semaglutide are currently undergoing rigorous evaluation in phase 3 clinical trials.Furthermore, other promising drugs, including orforglipron, BI 456906, and retartrutide, are progressing to phase 3 studies, expanding the therapeutic options for obesity management.In personalized patient care, physicians play a crucial role in accurately identifying individuals who genuinely require pharmacotherapy and selecting appropriate AOMs based on individual patient characteristics.By integrating evidence-based interventions and considering the unique needs of patients, healthcare professionals significantly contribute to the success of obesity management strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 The percentage of participants achieving ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% weight loss for each medication. Data were extracted from the following trials: XENical in the Prevention of Diabetes in Obese Subjects (XENDOS; orlistat),8 Contrave Obesity Research I (COR-I; naltrexone/bupropion [NB] extended-release [ER]),23 Satiety and Clinical Adiposity-Liraglutide (SCALE) Obesity and Prediabetes and its extension (liraglutide 3.0 mg),37,40 EQUIP (phentermine/topiramate [P/T] ER 1 year),49 SEQUEL (P/T ER 2 years),31 Semaglutide Treatment Effect in People with obesity (STEP) 1 (semaglutide 2.4 mg),13 and SURMOUNT-1 (tirzepatide 15 mg).48](https://figures.cochat.ai/paper-figures/506dbdfc48e84bddbe64b4302c180eb6/approved-anti-obesity-medications-in-2022-ksso-guidelines-and-the-promise-of-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-obesity medications have been approved by the U.S. Food and Drug Administration (FDA), including orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide, and tirzepatide, while newer agents such as orforglipron and retatrutide continue to emerge through late-phase trials [2,3,4,5,6,7].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Orlistat was consistently associated with oily stools, fecal urgency, and flatulence with discharge, occurring in 15–30% of users [2,5,20]; fat soluble vitamin malabsorption and rare cases of gallstones, kidney stones, liver injury, and pancreatitis were noted as well.”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sympathomimetic agents such as phentermine and combinations like phentermine/topiramate or naltrexone/bupropion, produced fewer GI events overall.”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common effects were mild constipation, dry mouth, or dysgeusia [2,3,5].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Orlistat causes mechanism-specific adverse effects including steatorrhea, fecal urgency, and oily stools, due to fat malabsorption [2,5].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundFuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Benefits and Risks of Bariatric Surgery in Adults: A Review
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020) · JAMA · doi:10.1001/jama.2020.12567 · Cited by 1,251
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundGreenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundKhera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533
Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347
Ravussin, E., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 332
Guerciolini, R. (1997) · PubMed · Cited by 331
Kadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00008-0 · Cited by 330
Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315
Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA · doi:10.1001/jama.2016.1558 · Cited by 273
Phentermine and topiramate for the management of obesity: a review
Uwaifo, G., Cosentino, & Conrad, A. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s31443 · Cited by 242
Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss
Billes, S. K., Sinnayah, P., & Cowley, M. A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.04.004 · Cited by 242 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundStructural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202
Fulfilling the Promise of "Biased" G Protein–Coupled Receptor Agonism
Luttrell, L. M., Maudsley, S., & Bohn, L. M. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099630 · Cited by 190
Weight Regain After Bariatric Surgery: Prevalence, Etiology, and Treatment
Velapati, S. R., Shah, M., Kuchkuntla, A. R., Abu-dayyeh, B., Grothe, K., Hurt, R. T., & Mundi, M. S. (2018) · Current Nutrition Reports · doi:10.1007/s13668-018-0243-0 · Cited by 170 · cited 1×
“(3) For long-term weight management, it is recommended to use”
BackgroundActivation of the GLP-1 receptor by a non-peptidic agonist
Zhao, P., Liang, Y.-L., Belousoff, M. J., Deganutti, G., Fletcher, M. M., Willard, F. S., Bell, M. G., Christe, M. E., Sloop, K. W., Inoue, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1902-z · Cited by 164
Kim, K.-K., Haam, J.-H., Kim, B. T., Kim, E. M., Park, J. H., Rhee, S. Y., Jeon, E., Kang, E., Nam, G. E., Koo, H. Y., et al. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23016 · Cited by 158 · cited 1×
“(4) If at least 5% weight loss is not achieved within 3 months of”
BackgroundSelf-citationGlucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147
Piteau, S., Olver, A., Kim, S.-J., Winter, K., Pospisilik, J. A., Lynn, F., Manhart, S., Demuth, H.-U., Speck, M., Pederson, R. A., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.115 · Cited by 130
Development of Cagrilintide, a Long-Acting Amylin Analogue
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00565 · Cited by 129
Therapeutic potential for GIP receptor agonists and antagonists
Irwin, N., & Flatt, P. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.001 · Cited by 114
Lingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · Obesity · doi:10.1002/oby.23621 · Cited by 113
Aronne, L. J., Halseth, A. E., Burns, C. M., Miller, S., & Shen, L. Z. (2010) · Obesity · doi:10.1038/oby.2009.478 · Cited by 100
Liraglutide: the therapeutic promise from animal models
Knudsen, L. B. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02499.x · Cited by 99 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundThe role of GIP in α-cells and glucagon secretion
El, K., & Campbell, J. E. (2020) · Peptides · doi:10.1016/j.peptides.2019.170213 · Cited by 96
Khera, R., Pandey, A., Chandar, A. K., Murad, M. H., Prokop, L. J., Neeland, I. J., Berry, J. D., Camilleri, M., & Singh, S. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.12.024 · Cited by 90
Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63
The Role of Pramlintide for Weight Loss
Dunican, K. C., Adams, N. M., & Desilets, A. R. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m210 · Cited by 50
Long-term pharmacotherapy for obesity and overweight
Padwal, R., Li, S., & Lau, D. (2002) · The Cochrane Database of Systematic Reviews (Protocol) · doi:10.1002/14651858.cd004094 · Cited by 41
Ardissino, M., Vincent, M., Hines, O., Amin, R., Eichhorn, C., Tang, A. R., Collins, P., Moussa, O., & Purkayastha, S. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa133 · Cited by 40 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundYazawa, R., Ishida, M., Balavarca, Y., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15064 · Cited by 23
Cardiovascular Safety and Superiority of Anti-Obesity Medications
Alobaida, M., Alrumayh, A., Oguntade, A. S., Al-Amodi, F., & Bwalya, M. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s311359 · Cited by 15 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundPratt, E. J., MA, X., LIU, R., Robins, D. A., Sloop, K. W., & Benson, C. (2022) · Diabetes · doi:10.2337/db22-336-or · Cited by 3
Research works printed but not linked: 1
- Kim KK. Peptides in obesity treatment. Arch Obes Metab 2022;1:4-13.
Cited by
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100
“Current guidelines recommend that, particularly for high-risk people with severe obesity or obesity-related complications, lifestyle programs can be combined with OMMs or metabolic bariatric surgery (MBS) 10–13 , with recent evidence suggesting that these interventions can be risk stratified 14,15 .”
Subramaniyan, V., & Hanim, Y. U. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01729-1 · Cited by 112
“However, when employing strategy-related pharma-cotherapy for obesity management, scientists and healthcare providers should adhere to several core guidelines [86].”
Pan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., et al. (2024) · Obesity · doi:10.1002/oby.24002 · Cited by 71
“Other studies have also reported similar results in which tirzepatide improved metabolic conditions of patients with mild to moderate adverse effects [76].”
ResultXie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54
GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Sioutas, G. S., Mualem, W., Reavey-Cantwell, J. F., & Rivet, D. J. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2020 · Cited by 59
Metadata
- Authors
- Jeon, E., Lee, K. Y., & Kim, K.-K.
- Affiliations
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University College of Medicine, Incheon, Korea
- Gachon University (KR)
- Corresponding author
- Kim, Kyoung-Kon
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2023-06-23
- Volume
- 32
- Issue
- 2
- Pages
- 106-120
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC10327684
- OpenAlex
- W4381610885
- Cited by
- 39
- References
- 69
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 14 · 2023: 5
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- anti-obesity drugs, obesity pharmacotherapy, orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, tirzepatide, orforglipron, obesity treatment, drug approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.